祥生医疗(688358) - 2025 Q1 - 季度财报

Financial Performance - Revenue for Q1 2025 was CNY 127.71 million, a decrease of 9.16% compared to CNY 140.60 million in the same period last year[4] - Net profit attributable to shareholders was CNY 41.61 million, down 8.62% from CNY 45.54 million year-on-year[4] - Basic and diluted earnings per share were both CNY 0.37, reflecting a decline of 9.76% from CNY 0.41 in the previous year[5] - Operating profit for Q1 2025 was ¥47.20 million, a decline of 9.3% compared to ¥52.41 million in Q1 2024[20] - Net profit for Q1 2025 was ¥41.61 million, down 8.5% from ¥45.54 million in Q1 2024[20] Cash Flow and Liquidity - Net cash flow from operating activities decreased by 20.14% to CNY 21.04 million, compared to CNY 26.34 million in the same period last year[5] - Cash flow from operating activities for Q1 2025 was ¥21.04 million, down 20.3% from ¥26.34 million in Q1 2024[24] - Cash and cash equivalents at the end of Q1 2025 increased to ¥847.61 million from ¥239.77 million at the end of Q1 2024[25] - The company's cash and cash equivalents increased to RMB 1,016,854,712.62 from RMB 985,616,661.93, representing a rise of about 3.2%[15] Assets and Liabilities - Total assets increased by 1.56% to CNY 1,621.89 million from CNY 1,597.01 million at the end of the previous year[4] - The company's total liabilities decreased to RMB 159,670,323.30 from RMB 176,423,213.57, a decline of about 9.5%[17] - Total current liabilities decreased to RMB 149,367,227.11 from RMB 166,785,376.57, a reduction of approximately 10.5%[16] - The company's total equity increased to RMB 1,462,219,998.56 from RMB 1,420,586,554.05, reflecting a growth of about 2.8%[17] Research and Development - R&D expenses totaled CNY 17.46 million, representing 13.67% of revenue, a slight decrease from 13.74% in the previous year[5] - Research and development expenses for Q1 2025 were ¥17.46 million, a decrease of 11.2% from ¥19.66 million in Q1 2024[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 6,509[10] - The largest shareholder, Wuxi Xiangsheng Investment Co., Ltd., holds 40.46% of the shares, totaling 45,360,000 shares[11] Other Financial Metrics - Financial expenses increased by 36.10%, primarily due to exchange rate fluctuations leading to increased foreign exchange losses[8] - The company reported non-recurring gains of CNY 2.74 million for the period[7] - The company reported a decrease in other comprehensive income, with a net loss of ¥518.53 thousand in Q1 2025 compared to a gain of ¥5.60 thousand in Q1 2024[20] - Accounts receivable rose to RMB 182,887,395.62, up from RMB 161,693,930.83, indicating an increase of approximately 13.1%[15] - Inventory decreased to RMB 107,496,307.15 from RMB 126,328,601.45, showing a decline of about 14.9%[15] - The non-current assets totaled RMB 195,821,486.94, slightly up from RMB 191,975,337.83, indicating a growth of approximately 2.0%[16] - The company's retained earnings increased to RMB 398,597,640.81 from RMB 356,983,110.49, representing a growth of approximately 11.6%[17] - The company experienced a net cash inflow from investment activities of ¥9.50 million in Q1 2025, slightly up from ¥9.44 million in Q1 2024[25]